PharmaCyte Biotech (PMCB) Non Operating Interest Expenses (2010 - 2022)
PharmaCyte Biotech's (PMCB) quarterly Non Operating Interest Expenses came in at $1058.0 in Q4 2022, up 120.42% year-over-year from $480.0 in Q4 2021, and down 72.91% quarter-over-quarter from $3906.0 in Q3 2022.
Powered by 
Analysis
PharmaCyte Biotech (PMCB) Non Operating Interest Expenses (2010 - 2022) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Non Operating Interest Expenses for 11 consecutive years, with $1058.0 the latest figure, recorded in Q4 2022.
- On a quarterly basis, Non Operating Interest Expenses rose 120.42% year-over-year to $1058.0 in Q4 2022; TTM through Apr 2023 was $4964.0, a 138.65% increase from a year earlier, with the FY2022 full-year figure at $509.0, down 83.29% from the prior year.
- Non Operating Interest Expenses was $1058.0 for Q4 2022 at PharmaCyte Biotech, down from $3906.0 in the prior quarter.
- Over five years, Non Operating Interest Expenses peaked at $3906.0 in Q3 2022 and troughed at $249.0 in Q1 2021.
- A 3-year average of $1260.3 and a median of $1040.0 in 2021 frame the typical range for Non Operating Interest Expenses.
- Across the five-year window, Non Operating Interest Expenses fell 29.1% in 2021 and surged 144.12% in 2022, its largest moves.
- Over 3 years, Non Operating Interest Expenses stood at $677.0 in 2020, then declined by 29.1% to $480.0 in 2021, then surged by 120.42% to $1058.0 in 2022.
- The last three Non Operating Interest Expenses figures came in at $1058.0 (Q4 2022), $3906.0 (Q3 2022), and $480.0 (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 4.00 Bn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -5.80 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 14.37 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 2.95 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 160,000.00 |
| 10 | PharmaCyte Biotech | 3.98 Mn | 3.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 31, 2022 | 1,058.00 |
| Jul 31, 2022 | 3,906.00 |
| Oct 31, 2021 | 480.00 |
| Jul 31, 2021 | 1,600.00 |
| Apr 30, 2021 | 1,040.00 |
| Jan 31, 2021 | 249.00 |
| Oct 31, 2020 | 677.00 |
| Jul 31, 2020 | 1,880.00 |
| Apr 30, 2020 | 453.00 |
| Apr 30, 2017 | 483.00 |
| Jan 31, 2017 | 131.00 |
| Oct 31, 2016 | 356.00 |
| Jul 31, 2016 | 569.00 |
| Apr 30, 2016 | 239.00 |
| Jan 31, 2016 | 126.00 |
| Oct 31, 2015 | -430.00 |
| Jul 31, 2015 | 632.00 |
| Apr 30, 2015 | -1,305.00 |
| Jan 31, 2015 | 1,518.00 |
| Oct 31, 2014 | 2,073.00 |